Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Therapeutic cancer vaccines are emerging as a significant approach for oncologic indications.
• Current FDA-approved vaccines and EMA-approved monotherapy show modest effects.
• Combinations with radiotherapy, hormone therapy, immunotherapy, and chemotherapy are being explored to enhance efficacy.

Purpose of the Study:

• To review the rationale behind combining therapeutic cancer vaccines with other modalities.
• To discuss clinical trial experiences and future directions in cancer vaccine therapy.
• To highlight promising developments in novel therapeutic cancer vaccines.

Main Methods:

• Review of preclinical and clinical data on combination therapies.
• Analysis of studies combining checkpoint inhibitors with vaccines.
• Examination of novel methods for identifying targetable neoantigens for personalized vaccines.

Main Results:

• Combination therapies, particularly with checkpoint inhibitors, show potential for immunogenic intensification and favorable outcomes.
• Personalized vaccine development using neoantigens is a promising area.
• Existing monotherapies have shown modest treatment effects.

Conclusions:

• Combining therapeutic cancer vaccines with other treatments, especially immunotherapy and checkpoint inhibitors, can enhance immune response and efficacy.
• Personalized vaccine strategies hold significant promise for future cancer treatment.
• Further research and clinical trials are essential to advance novel therapeutic cancer vaccines toward broader approval and application.